Cyclerion Therapeutics Valuation
Is CYCN undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Analyst Forecast
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CYCN?
Other financial metrics that can be useful for relative valuation.
| What is CYCN's n/a Ratio? | |
|---|---|
| n/a Ratio | 0x |
| n/a | n/a |
| Market Cap | US$27.98m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 4.9x |
| Enterprise Value/EBITDA | -0.1x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does CYCN's PS Ratio compare to its peers?
| Company | PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 15.5x | ||
ACOR Acorda Therapeutics | 0.2x | n/a | US$22.4m |
NHWK NightHawk Biosciences | 4.3x | 58.6% | US$29.8m |
SGTX Sigilon Therapeutics | 1.9x | 1.0% | US$23.2m |
CMRA Comera Life Sciences Holdings | 55.6x | n/a | US$30.6m |
CYCN Cyclerion Therapeutics | 18.1x | n/a | US$28.0m |
Price-To-Sales vs Peers: CYCN is expensive based on its Price-To-Sales Ratio (18.1x) compared to the peer average (15.5x).
Price to Earnings Ratio vs Industry
How does CYCN's PE Ratio compare vs other companies in the US Biotechs Industry?
Price to Sales Ratio vs Fair Ratio
What is CYCN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 18.1x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate CYCN's Price-To-Sales Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of CYCN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate CYCN's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate CYCN's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.